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Abstract There is a debate whether triplet or doublet
chemotherapy should be used as a first-line treatment
in patients with advanced or metastatic esophagogastric
cancer. Therefore, here we will review the available lit-
erature to assess the efficacy and safety of triplet versus
doublet chemotherapy as a first-line treatment in pa-
tients with advanced esophagogastric cancer. We
sea rched MEDLINE, Embase , and CENTRAL
(Cochrane Central Register of Controlled Trials) be-
tween 1980 and March 2015 for randomized controlled
phase II and III trials comparing triplet with doublet
chemotherapy and abstracts of major oncology meetings
from 1990 to 2014. Twenty-one studies with a total of
3475 participants were included in the meta-analysis for
overall survival. An improvement in overall survival
(OS) (hazard ratio (HR) 0.90, 95 % confidence interval
(CI) 0.83–0.97) and progression-free survival (PFS) (HR
0.80, 95 % CI 0.69–0.93) was observed in favor of
triplet. In addition, the use of triplet was associated with
better objective response rate (ORR) (risk ratio 1.25,
95 % CI 1.09–1.44) compared to doublet. The risks of
grade 3–4 thrombocytopenia (6.2 vs 3.8 %), infection
(10.2 vs 6.4 %), and mucositis (9.7 vs 4.7 %) were
statistically significantly increased with triplet compared
to doublet. This review shows that first-line triplet ther-
apy is superior to doublet therapy in patients with ad-
vanced esophagogastric cancer. However, the survival
benefit is limited and the risks of grade 3–4 thrombo-
cytopenia, infection, and mucositis are increased.
Keywords First-line treatment . Triplet chemotherapy .
Doublet chemotherapy . Palliative chemotherapy . Esophageal
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1 Introduction
Gastric and esophageal cancers are respectively the sec-
ond and the sixth most common cause of cancer-related
deaths worldwide. The only potentially curative option
involves resection. Unfortunately, the majority of pa-
tients presents with advanced disease or develops me-
tastases after treatment with curative intent. In these
patients, palliative systemic chemotherapy improves sur-
vival and quality of life, compared to best supportive
care [1–3].
Combination therapies have been associated with sub-
stantially higher response rates and survival compared to
monotherapy [4, 5]. However, the optimal regimen for
first-line palliative chemotherapy has yet to be clearly
established and the question whether a three-drug
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regimen is more effective than a potentially less toxic
doublet is a point of debate. A Cochrane review pub-
lished in 2010 concluded that Btwo and three-drug reg-
imens including 5-FU, cisplatin, with or without an
anthracycline are reasonable treatment options [6].^ This
ambiguity is reflected in various guidelines. According
to the National Comprehensive Cancer Network
(NCCN) guidelines of 2015 two-drug regimens are pre-
ferred and three-drug cytotoxic regimens should be re-
served for medically fit patients with good performance
scores and access to frequent toxicity evaluation [7].
The European Society for Medical Oncology (ESMO)
guidelines of 2013 state that Bcombination regimens in-
corporating a platinum agent and a fluoropyrimidine are
generally used. It remains controversial whether a triplet
regimen is needed [8].^ In recently published random-
ized trials introducing targeted therapies in first-line
treatment, mainly doublets have been used as the back-
bone chemotherapy [9–11], although one trial used a
triplet [12].
Therefore, here we will systematically review the
existing literature on triplet or doublet therapy in terms
of overall survival, progression-free survival, objective




A search was conducted at the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, and
EMBASE up to March 2015. The search strategy
contained medical subject headings (MESH) and text
words for esophageal and gastric cancer and all
established chemotherapy compounds in esophageal
and gastric cancer. We searched all abstracts from the
American Society of Clinical Oncology (ASCO) and the
ESMO conferences held between 1990 and 2014. The
research question was registered in PROSPERO in Sep-
tember 2014 (registration: CRD42014014480).
2.2 Study selection
Randomized phased II or III studies were included. We
included studies in abstract form only if information on
study design, characteristics of participants, interven-
tions, and outcomes was available in English. We ex-
cluded crossover studies and quasi randomized studies.
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Table 1 Characteristics of the included studies
Study Number Arms Efficacy Age Sex Disease status ECOG
OS PFS Median Range Male LA ME 0–1 ≥2
Median
months
N % N % N % N % N %
Ajani 2005 [16] 79 DTX+Cis+FU 9.6 NA 57 21–83 53 70 4 6 72 95 79* 100 0 0
76 DTX+Cis 10.5 NA 57 30–76 61 77 1 1 75 95 75 99 1 1
Al-Batran 2013 [17] 72 DTX+Ox+FU+LV 17.3 9.1 69 65–81 51 71 22 31 50 69 67 93 5 7
71 Ox+FU+LV 14.4 6.7 70 65–82 45 63 22 32 49 68 65 92 6 9
Cullinan1985 [35] 51 FU+Doxo+MMC NA NA 60# NA 39 76 20 39 31 61 32 63 19 37
49 Doxo+FU NA NA 63# NA 37 76 18 37 31 63 33 67 16 33
Douglass 1984 [36] 39 FU+Doxo+Me 24.5 NA 59.5 43–76 28 71 0 0 39 100 30 77 9 23
46 FU+Doxo+MMC 29.5 NA 61.0 32–81 35 76 0 0 46 100 30 65 16 35
48 FU+Me 13.5 NA 62.0 24–79 38 80 0 0 48 100 35 72 13 28
46 Doxo+MMC 19.0 NA 58.0 33–78 37 80 0 0 46 100 28 61 18 39
Guimbaud 2014 [18] 209 Epi+Cis+Cape 9.5 5.3 61 28–84 154 74 36 17 173 83 169 81 36 17
207 FU+Iri 9.7 5.7 61 29–81 155 75 31 15 176 85 173 84 27 13
Kim 1993 [37] 110 FU+Doxo+MMC 6.84 NA 54 19–77 68 62 NA NA NA NA 75 68 23 21
112 Cis+FU 8.61 NA 51 20–68 71 63 NA NA NA NA 83 74 20 18
Kim 2001 [38] 60 Epi+Cis+FU 8.5 NA 55 NA 45 75 3 5 57 95 54 90 6 10
60 Cis+FU 7.3 NA 56 NA 42 70 3 5 57 95 53 88 7 12
Koizumi 2004 [39] 33 5-DFUR+Cis+MMC 8.03 NA 58 36–79 19 58 NA NA NA NA 16 48 13 39
29 5-DFUR+Cis 5.97 NA 58 37–79 17 59 NA NA NA NA 25 86 6 24
KRCCG 1992 [40] 25 Epi+Cis+FU 6.9 NA NA NA NA NA NA NA NA NA NA NA NA NA
22 Cis+FU 4.0 NA NA NA NA NA NA NA NA NA NA NA NA NA
Li 2011 [41] 50 PTX+Cis+FU 10.6 NA 59 20–74 32 68 22 46 28 56 NA NA NA NA
44 Ox+FU 9.9 NA 58 20–75 31 70 17 41 27 61 NA NA NA NA
Lin 2009 [42] 13 FU+Ox+PTX NA NA 55 36–67 18 72 NA NA NA NA NA NA NA NA
12 FU+Iri NA NA 55 36–67 18 72 NA NA NA NA NA NA NA NA
Maiello 2011 [43] 36 Epi+Cis+Cap NA NA 58 39–74 22 60 NA NA NA NA NA NA NA NA
31 DTX+FU NA NA 61 44–75 23 74 NA NA NA NA NA NA NA NA
Park 2008 [19] 45 Cis+Iri+FU 10.5 6.2 52 29–70 30 67 0 0 45 100 38 84 7 16
46 Iri+FU 10.7 4.8 55 26–73 30 67 0 0 45 100 35 78 11 29
Roth 1999 [44] 61 Epi+Cis+FU 9.6 NA 54 NA 37 61 12 22 42 78 24 39 30 61
61 Epi+FU 7.1 NA 56 NA 42 69 16 30 40 84 27 44 29 56
Roth 2007 [20] 40 Epi+Cis+FU 8.3 NA 59 32–71 30 75 7 17 33 83 40 100 0 0
38 DTX+Cis 11.0 NA 58 40–70 29 76 7 18 31 82 38 100 0 0
41 DTX+Cis+FU 10.4 NA 61 35–78 30 73 2 5 39 95 41 100 0 0
Thuss-Patience 2005 [45] 45 Epi+Cis+FU 9.7 NA 63 33–75 36 80 1 2 44 98 44 98 1 2
45 DTX+FU 9.5 NA 62 34–75 29 64 1 2 44 98 42 95 2 4
Van Cutsem 2006 [22] 227 DTX+Cis+FU 9.2 NA 55 26–79 159 72 6 3 213 96 218 99 3 1
230 Cis+FU 8.6 NA 55 25–76 158 71 6 3 217 97 221 99 3 1
Van Cutsem 2015 [21] 89 DTX+Ox+FU 14.6 7.6 58 NA 61 69 0 0 89 100 87 98 2 2
86 DTX+Ox+Cap 11.3 5.6 59 NA 64 74 0 0 86 100 83 97 3 3
79 DTX+Ox 9.0 4.5 59 NA 51 65 0 0 79 100 77 99 1 1
Van Hoefer 2000 [23] 133 FU+Doxo+MTX 6.7 3.3 58 30–74 96 72 22 17 111 83 117 88 16 12
134 Cis+FU 7.2 4.1 57 24–74 91 68 21 16 113 84 114 85 20 15
132 Eto+FU+LV 7.2 3.3 59 25–74 90 68 22 17 110 83 120 91 12 9
Wang 2015 [46] 119 DTX+Cis+FU 10.2 7.2 57 19–80 81 68 30 25 89 75 115 97 4 3
115 Cis+FU 8.5 4.9 56 33–74 88 77 26 23 89 77 108 94 7 6
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adenocarcinoma of the distal esophagus, gastro-
esophageal junction, or stomach. They were not
previously treated with chemotherapy (or ≥6 months
ago in adjuvant setting). Treatment was defined as
Table 1 (continued)
Study Number Arms Efficacy Age Sex Disease status ECOG
OS PFS Median Range Male LA ME 0–1 ≥2
Median
months
N % N % N % N % N %
Yun 2010 [47] 44 Epi+Cis+Cap 13.8 6.5 55 35–71 28 64 NA NA NA NA 40 91 1 9
47 Cis+Cap 12.7 6.4 58 33–75 34 72 NA NA NA NA 41 87 4 13
OS overall survival, PFS progression-free survival, TTP time to progression, LA locally advanced, ME metastatic disease, ECOG Eastern Cooperative
Oncology Group performance status, NA not applicable, DTX docetaxel, PTX palictaxel, Cis cisplatin, FU fluorouracil, Cap capecitabine, 5-DFUR
doxifluridine, Ox oxaliplatin, Doxo doxorubicin, Epi epirubicin, Iri irinotecan, MTX methotrexate, MMC mitomycin C, Eto etoposide
*Karnofksi 80-100










































Fig. 2 When examining the subgroups, taxane and cisplatin showed a significant benefit
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intravenous or oral chemotherapy and we excluded
targeted therapy/biological therapy. Subgroups were
made and named after the third compound that was
added to the identical backbone in both arms. One sub-
group Bother^ was created that contained a triplet and a
doublet without the presence of an identical doublet
backbone.
2.3 Data extraction
NHM, MA, and EV conducted the search. NHM and EV
independently scrutinized titles and abstracts and if applicable
the full articles. HvL decided in case of disagreement between
NHM and EV. NHM, RM, and EV extracted the study char-
acteristics and outcome data. The primary outcome was over-
all survival (OS). Overall survival was defined as the time
between date of randomization and date of death or last date
of follow-up.
Secondary outcomes were progression-free survival (PFS),
objective response rate (ORR), and toxicity. Treatment-related
toxicity was defined as the highest grade of toxicity per par-
ticipant. Toxicity data, when available, were recorded if
scored as grade 3–4 toxicity.
2.4 Assessment of risk of bias
All selected studies were critically appraised using an
assessment form designed for the topic of this review
according to the Cochrane Handbook for Systematic
Reviews of Interventions 4.2.2 [13]. Risk of bias caused
by the absence of blinded review of CT scans was not
scored as high risk, since our primary outcome OS




















Fig. 3 A significant benefit was observed for PFS in favor of a triplet, which was mainly based on the addition of a taxane to the doublet
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EV assessed the risk of bias. HvL decided in case of
disagreement. If data were missing, we contacted the
first author to obtain further information.
2.5 Statistical analysis
Survival analysis was conducted using the intention-to-
treat population. A fixed model was used to calculate
the pooled hazard ratio (HR) estimate. HRs for
mortality were combined using an inverse variance
method based on a logarithmic conversion; 95 % confi-
dence intervals were used to determine the standard er-
ror using according to Tierney et al. [14]. The tradition-
al Q test and the I2 statistic were used to evaluate het-
erogeneity [15]. Where heterogeneity levels were mod-
erate or high (defined as I2≥50 %), we used a random
effects model. We repeated the primary analysis and
investigated the influence of risk of bias, continent of



































Fig. 4 The use of a triplet was associated with a better ORR compared to a doublet, which was mainly due to triplets with a fluoropyrimidine or taxane
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versus doublet without identical backbones, excluding
those trials with a high risk of bias score, trials con-
ducted in Asia, and trials of which the backbone was
not identical. All meta-analyses were performed with
Cochrane Review Manager, version 5.3.
3 Study outcomes
3.1 Description of studies
We identified 6715 articles from the database search. After
duplication, 1490 articles were screened on title and abstract.
Of these papers, 1467 were excluded: no randomized con-
trolled trials, reviews, and no comparison of a doublet versus
a triplet. Twenty-three articles were scrutinized as full text.
Finally, 21 randomized controlled studies were included in
the qualitative and quantitative analysis (Fig. 1.)
Twenty-two studies with in total 3475 participants
investigating a triplet versus a doublet were included.
Table 1 shows the characteristics of the studies included
in the meta- analysis.
3.2 Overall survival, progression-free survival,
and objective response rate
A significant improvement in OS with a low heteroge-
neity was observed in favor of a triplet (HR 0.90, 95 %
confidence interval (CI) 0.83–0.97, I2=29 %). When
examining the subgroups, especially the triplets with
fluoropyrimidine, taxane and cisplatin showed a signifi-
cant benefit (Fig. 2.). Also, a significant benefit was
observed for PFS in favor of a triplet (HR 0.80, 95 %
CI 0.69–0.93; Fig. 3), which was mainly based on the
addition of a taxane to the doublet.
In addition, the use of a triplet was associated with a better
ORR compared to a doublet (risk ratio=1.25, 95 % CI 1.09-
1.44). This was mainly due to triplets with a fluoropyrimidine
or taxane (Fig. 4.)
3.3 Risk of bias and sensitivity analyses
Data on outcome measures and risk of bias were re-
quested from all authors, but unfortunately only 28 %
of the corresponding authors provided further informa-
tion. Risk of bias assessments are shown in supplemen-
tary table 1 (Fig. 5).
A sensitivity analysis excluding those trials that were
conducted in Asia had no impact on the HR (0.90,
95 % CI 0.93–0.97) for OS (Fig. 6). Sensitivity analysis
excluding trials on the basis of low quality was not
possible due to the lack of data. Instead, studies with
Bunknown^ risk of bias on Brandom sequence^ and
Ballocation concealment^ were excluded in a sensitivity
analysis that showed a comparable HR of 0.92 (95 %
CI 0.84–1.02) (Fig. 7). Sensitivity analysis excluding
those trials that compared a triplet versus a doublet
without the presence of two identical compounds in
Fig. 5 Risk of bias assessment
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both arms showed a lower HR for OS of 0.79 (95 % CI
0.71–0.88 (Fig. 8)).
3.4 Toxicity
The risk of grade 3–4 thrombocytopenia (6.2 vs 3.7 %), in-
fection (10.2 vs 6.4 %), and mucositis (9.7 vs 4.7 %) was
significantly increased with a triplet compared to a doublet
(Table 2).
4 Discussion
Our systematic review and meta-analysis showed that a triplet
regimen was superior to a doublet regimen in terms of overall
survival, progression-free survival, and objective response
rate. However, hazard ratios were of limited clinical relevance
and toxicity grades 3 and 4 were significantly higher in the
triplet regimens.
T h e p o s i t i v e e f f e c t s o n OS o f a d d i n g a
fluoropyrimidine or a taxane to a doublet were based
on a relatively large number of patients (>500 patients),
making the findings in these subgroups very robust. The
favorable outcome of a triplet with cisplatin over a dou-
blet was based on a smaller number of patients. Our
results are in line with the previously published findings
by Wagner et al. [6] and are considered clinically rele-
vant given the widespread use of fluoropyrimidine,
taxane, and cisplatin containing triplets in routine prac-
tice in Europe [16–23].
Fig. 6 Sensitivity analysis excluding those trials that were conducted in Asia
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This contrasts with our finding that the addition of an
anthracycline to a doublet did not meet statistical sig-
nificance for OS. Although the addition of anthracycline
to the doublet showed an HR of 0.7, this was not sig-
nificant and the number of included patients did not
reach 200 in total. It should be noted that Wagner et al.
reported a significant HR of 0.77 (95 % CI 0.62–0.95)
for the addition of an anthracycline. This was based on
three randomized trials, of which the largest study
(81.7 % weight) investigated the comparison of an
anthracycline-based triplet with a non-anthracycline-
based triplet and showed a significant benefit for the
anthracycline-based triplet. The other two included stud-
ies were small and compared a triplet versus a doublet
but did not show significance. Based on Wagner’s data,
it may be concluded that an anthracycline-based triplet
is superior to a non-anthracycline-based triplet, but
based on our results, the true relevance of the addition
of anthracyclines to a doublet is doubtful.
In previous meta-analyses, results of PFS and ORR have
not been reported. We showed a significant improvement of
the secondary endpoint PFS and ORR in favor of triplet
chemotherapy, more specifically in the triplets adding a
taxane and a taxane or fluoropyrimidine to the combination,
respectively. Although in general in metastatic disease ORR
is not considered to be the most robust outcome measure, in
advanced esophagogastric cancer, ORR may be a clinically
relevant end point, given the high symptom burden that
patients may suffer from that may be alleviated by response
to treatment [1].
Fig. 7 Sensitivity analysis excluding studies with Bunknown^ risk of bias on Brandom sequence^ and Ballocation concealment^
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Substantial regional differences have been reported
between Asian and non-Asian populations in presenta-
tion and subtypes of esophagogastric cancer. For exam-
ple, in several Asian countries, patients present with
early disease, whereas in Western countries the majority
of patients present with advanced or metastatic disease
[24]. Secondly, while intestinal type of gastric cancer is
more prevalent in Asian countries, diffuse gastric cancer
is more common in non-Asian countries [25]. Neverthe-
less, a sensitivity analysis excluding the trials conducted
in Asia did not change our results. The sensitivity anal-
ysis on the basis of quality of studies in which we
excluded the studies with unknown risk of bias may
be very firm and can give an underestimation of the
quality of the excluded studies. As the findings are
consistent with those from the primary analysis, the
credibility of our results is strengthened.
Finally, the sensitivity analysis excluding the trials that did
not compare at least two identical compounds in both arms did
not cause a relevant change of the resulting HR with reduced
heterogeneity compared to the original analysis. Hence, the
results of this comparison can be considered to be highly
robust.
In general, toxicity was significantly higher in the
triplet combinations compared to the doublet. In the
context of palliative treatment, the degree of toxicity is
an important aspect that should be taken into account.
Hematologic toxicity has been shown to result in sub-
stantial psychological and economic burden [26]. How-
ever, others have observed that in patients with
Fig. 8 Sensitivity analysis excluding those trials that compared a triplet versus a doublet without the presence of two identical compounds in both arms
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advanced esophagogastric cancer, toxicity did not direct-
ly affect quality of life [1]. Similarly, in a review in
colorectal cancer, no correlation was noted between tox-
icity and quality of life [27].
Although the survival of patients treated with a triplet sig-
nificantly outweighed the survival of patients treated with a
doublet, overall, the survival gain was modest with a hazard
ratio of 0.90 of which the clinical relevancemay be questioned
[28]. However, the benefits of specific triplets, such as
fluoropyrimidine, cisplatin, or taxane-based triplets, were
more convincing. It should be noted that in this analysis, the
effect of second-line treatment has not been taken into consid-
eration. Since second-line treatment has become an accepted
standard of care [29–32], adding a third compound in the first
line may have become less relevant and could be reserved for
second-line or even third-line treatment. Indeed, sequential
chemotherapy has been shown equally effective compared to
combination-therapy patients with advanced colorectal cancer
[33]. However, in contrast to colorectal cancer, in advanced
esophagogastric cancer, after progression a substantial part of
patients may not be sufficiently fit to undergo second-line
treatment [4, 9, 34]. This underscores the relevance of clinical
studies incorporating new cytotoxic agents into a triplet,
which may be less toxic than currently used agents. For ex-
ample, the currently recruiting ACTION trial assesses the fea-
sibility of adding the new taxane nab-paclitaxel to the combi-
nation of capecitabine and oxaliplatin (clinicaltrials.gov
NCT02273713).
Several strengths and limitations of this meta-analysis
should be acknowledged. First, the findings regarding OS
were very robust, demonstrated by the series of sensitivity
analyses. Second, we defined subgroups on the basis of the
third chemotherapy compound in order to examine the effect
of the adding of a specific compound. However, caution is
needed, when interpreting the beneficial effect of triplet versus
doublet in terms of PFS because PFS was a secondary out-
come in only a limited amount of studies. Moreover, the ma-
jority of included studies were phase II studies. Missing infor-
mation regarding the PFS may under- or overestimate the gain
in PFS. Second, toxicity was not uniformly scored which pre-
cluded extensive analysis. Third, quality of life was not a
designated secondary outcome in most studies, and conse-
quently, no recommendations could be made in this respect.
Fourth, not all relevant sensitivity analyses could be conduct-
ed as planned, as only 28 % of the authors provided informa-
tion to evaluate the risk of bias. Fifth, our meta-analysis is not
based on individual patient data. Therefore, differences in in-
dividual baseline characteristics cannot be adjusted for.
In conclusion, addition of a fluoropyrimidine, cisplat-
in, or taxane to a doublet showed superior overall sur-
vival in first-line treatment of advanced esophagogastric
cancer, at the cost, however, of higher toxicity. There is
a need for new triplets with cytotoxic agents, which
may be less toxic than the currently used regimens.
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Table 2 Toxicity grade 3 or 4
Toxicity grade 3 or 4 Triplet Doublet
N Total % N Total % RR 95 % CI
Hematologic toxicity
Anemia 106 840 12.6 121 823 14.7 0.86 0.68–1.09
Neutropenia 543 1006 54.0 470 986 47.7 1.07 0.92–1.23
Neutropenic fever 46 385 11.9 46 367 12.5 0.95 0.50–1.82
Thrombocytopenia 61 986 6.2 37 962 3.8 1.57a 1.06–2.31
Non-hematologic toxicity
Fatigue 50 331 15.1 52 316 16.5 0.91 0.64–1.29
Infection 64 630 10.2 40 629 6.4 1.60a 1.09–2.33
Mucositis 59 607 9.7 28 591 4.7 2.20a 1.00–4.86
Nausea 85 665 12.8 63 648 9.7 1.34 0.98–1.82
Vomiting 84 728 11.5 81 716 11.3 1.04 0.78–1.38
Diarrhea 114 1260 9.0 98 1244 7.9 0.98 0.60–1.61
Toxicity-related deaths 68 1069 6.4 54 1052 5.1 1.24 0.89–1.74
RR relative risk, 95 % CI 95 % confidence interval
a Significant
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